Ryan Deschner News Today

Ardelyx, Inc. beats earnings expectations. Reported EPS is $-0.11, expectations were $-0.13. Ardelyx, Inc.

72-week data from Vera Therapeutics' Phase 2b ORIGIN trial on atacicept for IgA nephropathy. Analysts upgrade stock to Strong Buy, citing impressive efficacy and low-risk profile.

Vera Therapeutics' significant market movements! Discover the latest on atacicept in IgA nephropathy trials, analyst ratings, and FDA approvals.

Raymond James initiated coverage on Vera Therapeutics Inc (NASDAQ: VERA), a late-stage drug developer in the autoimmune kidney space. The lead asset, atacicept, is a BLyS/APRIL dual inhibitor fusion protein currently in a Phase 3 study in IgA Nephropathy (IgAN).

Raymond James initiated coverage of Ardelyx Inc (NASDAQ: ARDX), noting the company's two early-stage launches underway for the same molecule with differentiated pricing:

Operator: Hello, and thank you for standing by. Welcome to Intercept Pharmaceuticals Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

GILD earnings call for the period ending March 31, 2023.

Operator Welcome to the Q1 2021 Intercept Pharmaceuticals Earnings Call. My name is Anette, and Ill be your operator for todays call. [Operator Instructions] I will now turn the call over to Lisa DeFrancesco. Lisa, you may begin. Lisa DeFrancesco -- Senior Vice President of Investor Relations and Corporate Affairs Thank you. Good morning, and thank you for joining us on todays call. This morning, we issued a press release announcing our first quarter 2021 results and financial position, which ...

Operator Good morning, ladies and gentlemen, and welcome to the Jounce Therapeutics First Quarter 2021 Earnings Conference Call. [Operator Instructions]. I will now turn the call over to your host, Malin Deon with Jounce Therapeutics. Please go ahead. Malin Deon -- Manager, Investor Relations & Corporate Communications Thank you, operator. Good morning, and welcome to the Jounce Therapeutics first quarter conference call. This morning we issued a press release which outlines the topics that we...

Operator Welcome to the Viking Therapeutics 2021 first-quarter financial results conference call. [Operator instructions] As a reminder, this conference call is being recorded today, April 28th, 2021. I would now like to turn the conference over to Vikings manager of investor relations, Stephanie Diaz. Please go ahead, Stephanie. Stephanie Diaz -- Manager of Investor Relations Hello, and thank you all for participating in todays call. Joining me today is Brian Lian, Vikings president and CEO; ...